Standard
Effects of liraglutide on cardiovascular risk biomarkers in patients with type 2 diabetes and albuminuria : A sub-analysis of a randomized, placebo-controlled, double-blind, crossover trial. / von Scholten, Bernt Johan; Persson, Frederik; Rosenlund, Signe; Eugen-Olsen, Jesper; Pielak, Tomasz; Faber, Jens; Hansen, Tine W.; Rossing, Peter.
In:
Diabetes, Obesity and Metabolism, Vol. 19, No. 6, 2017, p. 901-905.
Research output: Contribution to journal › Journal article › Research › peer-review
Harvard
von Scholten, BJ, Persson, F, Rosenlund, S, Eugen-Olsen, J, Pielak, T
, Faber, J, Hansen, TW
& Rossing, P 2017, '
Effects of liraglutide on cardiovascular risk biomarkers in patients with type 2 diabetes and albuminuria: A sub-analysis of a randomized, placebo-controlled, double-blind, crossover trial',
Diabetes, Obesity and Metabolism, vol. 19, no. 6, pp. 901-905.
https://doi.org/10.1111/dom.12884APA
von Scholten, B. J., Persson, F., Rosenlund, S., Eugen-Olsen, J., Pielak, T.
, Faber, J., Hansen, T. W.
, & Rossing, P. (2017).
Effects of liraglutide on cardiovascular risk biomarkers in patients with type 2 diabetes and albuminuria: A sub-analysis of a randomized, placebo-controlled, double-blind, crossover trial.
Diabetes, Obesity and Metabolism,
19(6), 901-905.
https://doi.org/10.1111/dom.12884Vancouver
von Scholten BJ, Persson F, Rosenlund S, Eugen-Olsen J, Pielak T
, Faber J et al.
Effects of liraglutide on cardiovascular risk biomarkers in patients with type 2 diabetes and albuminuria: A sub-analysis of a randomized, placebo-controlled, double-blind, crossover trial.
Diabetes, Obesity and Metabolism. 2017;19(6):901-905.
https://doi.org/10.1111/dom.12884Author
von Scholten, Bernt Johan ; Persson, Frederik ; Rosenlund, Signe ; Eugen-Olsen, Jesper ; Pielak, Tomasz ; Faber, Jens ; Hansen, Tine W. ; Rossing, Peter. / Effects of liraglutide on cardiovascular risk biomarkers in patients with type 2 diabetes and albuminuria : A sub-analysis of a randomized, placebo-controlled, double-blind, crossover trial. In: Diabetes, Obesity and Metabolism. 2017 ; Vol. 19, No. 6. pp. 901-905.
Bibtex
@article{ba025435a5f84d0ba5a090680e97cf98,
title = "Effects of liraglutide on cardiovascular risk biomarkers in patients with type 2 diabetes and albuminuria: A sub-analysis of a randomized, placebo-controlled, double-blind, crossover trial",
keywords = "clinical trial, GLP-1 analogue, liraglutide",
author = "{von Scholten}, {Bernt Johan} and Frederik Persson and Signe Rosenlund and Jesper Eugen-Olsen and Tomasz Pielak and Jens Faber and Hansen, {Tine W.} and Peter Rossing",
year = "2017",
doi = "10.1111/dom.12884",
language = "English",
volume = "19",
pages = "901--905",
journal = "Diabetes, Obesity and Metabolism",
issn = "1462-8902",
publisher = "Wiley-Blackwell",
number = "6",
}
RIS
TY - JOUR
T1 - Effects of liraglutide on cardiovascular risk biomarkers in patients with type 2 diabetes and albuminuria
T2 - A sub-analysis of a randomized, placebo-controlled, double-blind, crossover trial
AU - von Scholten, Bernt Johan
AU - Persson, Frederik
AU - Rosenlund, Signe
AU - Eugen-Olsen, Jesper
AU - Pielak, Tomasz
AU - Faber, Jens
AU - Hansen, Tine W.
AU - Rossing, Peter
PY - 2017
Y1 - 2017
KW - clinical trial
KW - GLP-1 analogue
KW - liraglutide
U2 - 10.1111/dom.12884
DO - 10.1111/dom.12884
M3 - Journal article
C2 - 28105731
VL - 19
SP - 901
EP - 905
JO - Diabetes, Obesity and Metabolism
JF - Diabetes, Obesity and Metabolism
SN - 1462-8902
IS - 6
ER -
